Michaela E Johnson
Overview
Explore the profile of Michaela E Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Humenick A, Chen B, Johnson M, Yew W, Wattchow D, Sia T, et al.
Cell Mol Gastroenterol Hepatol
. 2025 Feb;
:101479.
PMID: 39978461
No abstract available.
2.
Lee K, Koeper I, Johnson M, Page A, Rowett D, Johnson J
Int J Qual Health Care
. 2023 Dec;
36(1).
PMID: 38155609
In today's complex healthcare landscape, exacerbated by resource constraints at various levels, optimization of health professionals' roles is becoming increasingly paramount. Interprofessional collaboration, underpinned by role recognition and teamwork, leads...
3.
Johnson M, Humenick A, Peterson R, Costa M, Wattchow D, Sia T, et al.
Front Neurosci
. 2022 Dec;
16:1072002.
PMID: 36532291
Background: In the human large bowel, sacral parasympathetic nerves arise from S2 to S4, project to the pelvic plexus ("hypogastric plexus") and have post-ganglionic axons entering the large bowel near...
4.
Bakker M, Johnson M, Corre L, Mill D, Li X, Woodman R, et al.
PLoS One
. 2022 May;
17(5):e0267969.
PMID: 35507635
Background: Admission to hospital introduces risks for people with Parkinson's disease in maintaining continuity of their highly individualized medication regimens, which increases their risk of medication errors. This is of...
5.
Burbulla L, Zheng J, Song P, Jiang W, Johnson M, Brundin P, et al.
JCI Insight
. 2021 Oct;
6(19).
PMID: 34622801
Current treatments for Parkinson's disease (PD) provide only symptomatic relief, with no disease-modifying therapies identified to date. Repurposing FDA-approved drugs to treat PD could significantly shorten the time needed for...
6.
Johnson M, Bergkvist L, Stetzik L, Steiner J, Meyerdirk L, Schulz E, et al.
Neurobiol Dis
. 2021 Sep;
159:105513.
PMID: 34536552
Autophagic dysregulation and lysosomal impairment have been implicated in the pathogenesis of Parkinson's disease, partly due to the identification of mutations in multiple genes involved in these pathways such as...
7.
Bergkvist L, Johnson M, Mercado G, Steiner J, Meyerdirk L, Schulz E, et al.
Exp Neurol
. 2021 Mar;
341:113693.
PMID: 33727096
The repurposing of drugs developed to treat type 2 diabetes for the treatment of Parkinson's disease (PD) was encouraged by the beneficial effect exerted by the glucagon-like peptide 1 (GLP-1)...
8.
Johnson M, Bergkvist L, Mercado G, Stetzik L, Meyerdirk L, Wolfrum E, et al.
Sci Rep
. 2020 Jun;
10(1):9242.
PMID: 32514004
Hyposmia is evident in over 90% of Parkinson's disease (PD) patients. A characteristic of PD is intraneuronal deposits composed in part of α-synuclein fibrils. Based on the analysis of post-mortem...
9.
Johnson M, Zhou X, Bobrovskaya L
J Chem Neuroanat
. 2019 Jan;
97:23-32.
PMID: 30690135
Loss of dopaminergic neurons in the substantia nigra (SN) is one of the pathological hallmarks in Parkinson's disease (PD). This neuron loss is accompanied by reduced protein and activity levels...
10.
Johnson M, Stecher B, Labrie V, Brundin L, Brundin P
Trends Neurosci
. 2018 Oct;
42(1):4-13.
PMID: 30342839
We hypothesize that Parkinson's disease (PD) pathogenesis can be divided into three temporal phases. During the first phase, 'triggers', such as viral infections or environmental toxins, spark the disease process...